Prediction of personalized therapeutic response in pediatric clivus chordoma: chemoresistance test Authors: Sérgio Cavalheiro, Lorena Favaro Pavon, Caroline Brunetto de Farias, Flávia Borelli Nascimento, Martina Lichtenfels, Jessica Benigno Rodrigues, Natalia Dassi, Andreia Cappellano, Patrícia Alesssandra Dastoli, Thais Cristina de Souza Melo, Fernando Suzuki, Rodrigo Akira Watanabe, Isaque Hyung Tong Kim, Francine Tesser-Gamba, Thais Biude Mendes, Franz Onish, Marcos Devanir Silva da Costa Published: 2026 ABSTRACT AbstractPrecision medicine has expanded therapeutic options for rare central nervous system tumors, yet actionable molecular targets remain limited in pediatric cases. Functional ex vivo drug-response assays may complement genomic approaches by identifying tumor-specific sensitivities. Clival chordoma is a rare, locally aggressive tumor generally considered chemotherapy-refractory, particularly in children. We report the prospective use of a functional drug-response platform (Bioverso Test) to guide treatment in a pediatric patient with recurrent metastatic clival chordoma. A four-year-old patient with intracranial and pulmonary disease underwent testing using three-dimensional tumor microspheroids. The assay demonstrated broad resistance, with relative sensitivity to irinotecan (CPT-11). Treatment with an irinotecan-based regimen (50 mg/m²/day, days 1–5) resulted in a marked clinical and radiological response after three cycles, with significant reduction of intracranial and pulmonary lesions and no severe toxicities. The response has been sustained for 14 months. This case illustrates the clinical utility of integrating functional drug-response data into real-time decision-making, supporting a role for functional precision oncology in rare and treatment-refractory pediatric tumors.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00432-026-06506-9.Keywords: Precision, Chemoresistance, CNS tumors, Microspheroids, Chordoma Introduction Tumors of the central nervous system (CNS) are one of the leading causes of cancer-related morbidity and mortality in the pediatric population, second only to hematologic neoplasms in terms of incidence (Ostrom et al. 2023). These neoplasms are characterized by marked biological heterogeneity—encompassing different histological, genetic, and epigenetic subgroups—which is reflected in the wide variability in prognosis and therapeutic response (Mackay et al. 2024). This complexity imposes limitations on standardized therapeutic approaches and reinforces the need for individualized strategies that consider the biological particularities of each tumor. In this context, precision neuro-oncology has emerged as a new paradigm by integrating molecular, epigenetic, and functional data to guide more effective and potentially less toxic therapeutic decisions. However, as highlighted by Villa et al. (Villa et al. 2024), despite advances enabled by next-generation sequencing (NGS), the clinical applicability of these data remains limited in rare pediatric tumors, in which the identification of molecular targets does not always translate into effective therapeutic options. Another major challenge in the treatment of pediatric CNS tumors relates to the toxicity associated with conventional systemic therapies. Children exposed to non-targeted chemotherapy are particularly susceptible to late adverse effects, including neurocognitive, endocrine, and functional impairments, with a significant impact on quality of life (Fernandes et al. 2023). Tumor chemoresistance arises from a complex interplay of biological mechanisms, including intratumoral heterogeneity, activation of drug efflux transporters, alterations in DNA damage response pathways, epigenetic modifications, and protective interactions within the tumor microenvironment. These processes can substantially reduce the effectiveness of cytotoxic therapies, even when adequate systemic drug exposure is achieved. Importantly, while molecular profiling has advanced the identification of potential therapeutic targets, it does not consistently predict functional drug response, particularly in rare pediatric tumors with limited actionable alterations. As a result, many patients are exposed to treatments with uncertain benefit and considerable toxicity. This gap underscores the need for complementary strategies capable of functionally assessing tumor sensitivity and resistance in a clinically relevant context. This gap highlights the need for functional platforms capable of capturing real-time tumor behavior under drug exposure, forming the rationale for the approach investigated in the present study. In recent years, functional strategies in precision oncology, such as three-dimensional models derived from fresh tumors, have shown potential to complement traditional molecular analyses (Jacob et al. 2020). Models based on tumor microspheroids and organoids are capable of partially reproducing key characteristics of the tumor microenvironment and intratumoral heterogeneity, allowing direct assessment of drug sensitivity and resistance (Vladimirova et al. 2023). In this context, in vitro chemoresistance platforms have emerged as a complementary tool in selected scenarios, providing functional data capable of supporting clinical decision-making, particularly in rare tumors and those refractory to conventional therapies (Pujadas et al. 2023). Among these strategies, the Bioverso Test represents an emerging approach for assessing tumor resistance, based on the three-dimensional culture of microspheroids derived from fresh tumor tissue, enabling functional analysis of cell viability in response to multiple antineoplastic agents (Sousa et al. 2024, Marcolin et al. 2023, Dos Santos et al. 2023). A recent study by Cavalheiro et al. (Cavalheiro et al. 2026) has demonstrated the technical feasibility and clinical applicability of the Bioverso Test (in vitro chemoresistance platform) in pediatric CNS tumors, reinforcing the translational potential of this test within precision oncology. These authors analyzed a cohort comprising 50 CNS tumor samples from pediatric patients; among these, seven cases of adamantinomatous craniopharyngioma exhibited a broad resistance profile to most of the chemotherapeutic agents tested, with consistent sensitivity only to temozolomide. Targeted therapeutic incorporation based on these findings resulted in significant volumetric tumor regression—approximately 50% after 12 treatment cycles—in a patient with recurrent disease who had previously undergone multiple surgical interventions and radiotherapy. These results provide preliminary evidence that chemoresistance assays may support the selection of potentially effective systemic therapies in neoplasms historically recognized for their limited responsiveness to chemotherapy. Clival chordoma exemplifies these therapeutic limitations. It is a rare primary bone tumor arising from remnants of the notochord and is characterized by slow but locally aggressive growth, high recurrence rates, and limited response to conventional chemotherapy regimens (Stacchiotti et al. 2023). In the pediatric population, chordoma often presents more aggressive biological behavior and a lack of effective systemic protocols, especially in cases of recurrence and metastatic disease (Young et al. 2023). These aspects reinforce the need for innovative and personalized therapeutic approaches. Therefore, the present study aimed to evaluate the in vitro chemoresistance platform (Bioverso Test) as a complementary tool to support precision neuro-oncology, highlighting its potential contribution to the individualization of chemotherapy treatment in pediatric CNS tumors, with emphasis on clival chordoma—a rare, biologically complex neoplasm with particularly challenging therapeutic management. In addition, we report a pediatric case of clival chordoma in which this test enabled identification of the tumor’s resistance profile to chemotherapeutic agents, thus guiding clinical management and culminating in a significant therapeutic response. Results Identification of genetic variants in the tumor sample Genomic analysis via NGS using the Oncomine Childhood Cancer Research Assay (OCCRA) panel did not identify clinically relevant variants in the clival chordoma sample analyzed. The screening included the search for single nucleotide variants and small insertions/deletions (indels) across all exons of the genes included in the panel, as well as evaluations of structural rearrangements for the detection of gene fusions. No pathogenic alterations were detected in any of the analyzed categories. Evaluation of the in vitro chemoresistance test The Bioverso Test (in vitro chemoresistance assay) performed on the clival chordoma sample (Fig. 1a) demonstrated resistance to most of the agents evaluated, with the exception of irinotecan (CP-11) at doses D1 = 50 µM and D2 = 110 µM, which showed tumor viabilities of 30.3% and 15.5%, respectively (Fig. 1b). a Collection and fresh processing of clival chordoma tissue, and microspheroid culture; b application of the Bioverso Test to clival chordoma microspheroids (patient SFC_NP:152907) and microscopy of untreated control microspheroids (b1), microspheroids treated with irinotecan (CDT-11_D1) (b2), and microspheroids treated with irinotecan (CDT-11_D2) (b3); c apoptosis assay by flow cytometry (Annexin V/PI) in microspheroid cells, confirming the findings of the Bioverso Test Morphological analysis of the microspheroids treated with irinotecan (CP-11) [D1/D2] (Figs. 1b2 and 1b3) revealed increased dispersion of tumor cells compared with that in the control (Fig. 1b1), reflecting (i) penetration of the chemotherapeutic agent into the microspheroids, (ii) dispersion or loss of cellular cohesion, (iii) reduced adhesion within the three-dimensional microspheroid structure, and (iv) toxicity to the agent under investigation. These cytotoxic effects corroborated the Annexin V/PI apoptosis induction assay (programmed cell death), performed by flow cytometry, in which clival chordoma microspheroid cells showed 85.8% and 72.1% cell death at doses D2 and D1, respectively, as indicated by the test (Fig. 1c). Clinical case report Patient information The patient was a four-year-old boy who was previously healthy, with no known comorbidities, relevant family history, or noteworthy environmental exposures. Chief complaint and history of present illness The patient initially presented with headache, neck pain, and torticollis that progressively worsened over five months. Conservative treatment with analgesics, anti-inflammatory drugs, and physiotherapy for one month was ineffective, and the patient later developed worsening cervical deformity with kyphosis, leading to referral for orthopedic evaluation. Clinical findings Clinical examination revealed restricted cervical mobility associated with progressive postural deformity. No focal neurological deficits were evident at the initial presentation. Diagnostic evaluation Magnetic resonance imaging (MRI) MRI of the brain and cervical spine revealed an infiltrative lesion in the clival region with compressive effects on adjacent cervical structures and the brainstem (Fig. 2), without evidence of metastatic dissemination on whole neural axis imaging. Tumor biopsy confirmed the diagnosis of clival chordoma, with immunohistochemical findings supporting this diagnosis and a Ki-67 proliferation index of 20–30%. Next-generation sequencing (OCCRA panel) did not identify clinically relevant pathogenic variants. Clinical and radiological timeline of a pediatric patient with recurrent clival chordoma managed with translational precision medicine: (1) Initial presentation: contrast-enhanced axial and sagittal magnetic resonance imaging (MRI) demonstrating a large clival lesion with significant skull base involvement and compression of adjacent brainstem structures; (2) Postoperative stage following subtotal resections, occipito-cervical fixation, and intensity-modulated radiotherapy (total dose: 74 Gy), promoting local disease control at the primary site; (3) Six months after radiotherapy, brain MRI revealed intraparenchymal metastatic lesions, including hemorrhagic metastasis, associated with pulmonary metastatic disease; (4) After surgical treatment of the hemorrhagic metastatic lesion, the fresh tumor sample was submitted to the Bioverso functional chemoresistance assay, which identified sensitivity to irinotecan. The patient subsequently underwent irinotecan-based chemotherapy combined with stereotactic radiosurgery, achieving sustained clinical and radiological response; (5) At the 14-month follow-up after treatment initiation, imaging demonstrated no evidence of active tumor recurrence Therapeutic interventions To improve local disease control, the patient underwent two consecutive partial tumor resections. The first procedure was performed via a transsphenoidal approach, and the second via a suboccipital approach, combined with fixation of the C3 and C4 cervical vertebrae. The interval between the initial biopsy and the last partial resection was approximately three months. Surgical treatment was complemented with intensity-modulated radiation therapy initiated one month after the last surgery, with a total dose of 74 Gy, fractionated into 37 sessions of 200 cGy. Six months after completing radiation therapy, the tumor recurred with multiple intraparenchymal brain and pulmonary metastases (Fig. 2). Surgical drainage was performed on the largest supratentorial lesion, located in the right precentral gyrus, which presented intralesional hemorrhage. Histopathological analysis confirmed tumor recurrence with morphological and immunohistochemical characteristics identical to those of the primary tumor. Notably, no radiological evidence of active disease was observed at the primary clival site at the time of recurrence. Given the disease progression and absence of standardized chemotherapy regimens for pediatric chordoma, the in vitro chemoresistance test (Bioverso Test) was performed using freshly obtained tumor tissue, which showed a significant reduction in tumor cell viability with irinotecan (CP-11) D2 = 110 µM. Based on the functional profile identified, which demonstrated tumor sensitivity to irinotecan in the context of broad resistance to the other agents tested, the multidisciplinary neuro-oncology team selected the Brazilian Protocol for High-Risk Rhabdomyosarcoma, which proposes the use of irinotecan (50 mg/m²/day, D1–D5) in the initial cycles. The regimen was subsequently followed by combination chemotherapy, including eight cycles of ifosfamide 3 g/m²/day (D1–D3) + etoposide 150 mg/m²/day (D1–D3) and seven cycles of vincristine 1.5 mg/m² (D1) + actinomycin D 0.045 mg/kg (D1) + cyclophosphamide 1.8 g/m² (D1). Although the protocol allows different possible sequences, the prioritization of cycles containing irinotecan was guided by the ex vivo sensitivity profile identified. After the first three cycles, MRI evaluation of the brain and neural axis showed a global radiological response, with significant reduction in lesions, including those located within the brain parenchyma. As part of the treatment for brain metastases, the patient also underwent focal radiotherapy delivered by stereotactic radiosurgery, receiving a single dose of 16 Gy to the lesion in the right precentral gyrus and doses of 20 Gy to the gross tumor volume (GTV) and 18 Gy to the planning target volume (PTV = GTV + 2 mm) in six additional metastatic lesions. Follow-up and outcomes After three cycles of systemic chemotherapy, MRI reevaluation of the brain and neural axis, combined with chest computed tomography, demonstrated a favorable radiological response with significant reduction of brain lesions and pulmonary metastatic (Fig. 2). The patient remained on chemotherapy, with favorable clinical progress and gradual reduction of contrast-enhancing metastatic areas. Only residual lesions with low signal intensity on susceptibility-weighted imaging sequences were observed, corresponding to previously treated metastatic sites. No severe treatment-related toxicities were observed. At the most recent follow-up (approximately 14 months after treatment initiation), the patient continues to demonstrate sustained disease control, with no evidence of tumor progression. Recent imaging findings were consistent with treatment-related changes, particularly radionecrosis, without signs of active disease recurrence. Clinically, the patient showed preserved functional status despite transient neurological worsening associated with radionecrosis. At the latest evaluation, the patient remained alert, interactive, and communicative, with adequate oral intake and stable systemic condition. Motor assessment revealed active movement in all four limbs, with preserved strength on the right side and left-sided weakness, more pronounced proximally. The patient was able to maintain sitting and standing positions independently and ambulate without assistance, although with a tendency to seek unilateral support. According to caregiver report, the child remains functionally independent in daily activities. During the follow-up period, the patient experienced focal seizures associated with imaging findings of edema and small hemorrhagic foci, which were clinically managed with antiepileptic therapy. Importantly, no further seizure activity has been reported after treatment adjustment. Discussion Understanding and overcoming chemoresistance remain among the greatest challenges in the treatment of brain tumors, particularly high-grade gliomas and recurrent pediatric neoplasms. In recent decades, advances in genomics and other omics-based approaches have transformed the molecular understanding of these tumors; however, such information in isolation is often insufficient to predict effective therapeutic responses (Flobak et al. 2022, Cheng et al. 2025). In this context, functional drug-response tests, which directly evaluate tumor cell behavior under drug exposure, have emerged as complementary tools for identifying active agents and, importantly, for characterizing resistance mechanisms that escape traditional molecular analysis (Lau et al. 2020, Napoli et al. 2022). The microspheroid model proposed here enabled in vitro reproduction of genetic and phenotypic tumor heterogeneity, while partially preserving features of the tumor microenvironment (Vlachogiannis et al. 2018, Brabetz et al. 2018). This three-dimensional approach provides greater biological representativeness than two-dimensional cultures, as it mimics cell–cell adhesion, hypoxia, and drug penetration gradients observed in vivo (Vinci et al. 2012, Zanoni et al. 2016, Jeppesen et al. 2017). Although this model more closely reflects clinically observed response patterns compared to conventional monolayer systems (Lago et al. 2023), it still only partially recapitulates the full complexity of the tumor microenvironment. In this context, the present study: (i) performed genomic analysis by NGS using the OCCRA panel, with no clinically relevant variants identified in the clival chordoma sample; and (ii) established and validated methodological strategies for applying an in vitro functional chemoresistance platform (Bioverso Test), based on dissociation of fresh tumor tissue and generation of three-dimensional microspheroids for pharmacological response assessment. This approach enabled functional evaluation of cell viability across multiple chemotherapeutic agents, demonstrating technical feasibility and potential clinical applicability. Using this methodology, we described the case of a four-year-old patient with clival chordoma associated with intraparenchymal brain metastases. The assay revealed a broad chemoresistance profile to most tested agents, with the exception of irinotecan (CP-11), which showed a low resistance index [D2 = 110 µM] and tumor viability of approximately 15.5%, corroborated by apoptosis analysis (Annexin V/PI). Notably, irinotecan is a prodrug converted in vivo to its active metabolite SN-38, a potent inhibitor of topoisomerase I responsible for its cytotoxic effect. Based on this sensitivity profile, treatment with irinotecan (50 mg/m²/day, D1–D5) was initiated during the initial cycles of the Brazilian Protocol for Rhabdomyosarcoma (Brabo et al. 2022). After three cycles of combined chemotherapy for high-risk disease, a global radiological response was observed, including reduction of brain parenchymal and pulmonary metastatic lesions, consistent with the functional assay findings. Although the patient has demonstrated sustained clinical and radiological response, longer follow-up is required to assess durability and long-term disease control. Importantly, this report extends beyond prior studies primarily focused on the feasibility of organoid or spheroid models. In the present case, functional drug-response data were prospectively integrated into real-time clinical decision-making, directly influencing treatment prioritization. The assay not only demonstrated retrospective concordance with clinical evolution but also actively contributed to defining the therapeutic strategy. To our knowledge, this represents one of the first such applications in pediatric clival chordoma. Although the Brazilian Protocol for High-Risk Rhabdomyosarcoma includes multiple cytotoxic agents, the prioritization of irinotecan-containing cycles was deliberately guided by the ex vivo chemoresistance profile. While the multimodal regimen precludes isolated causal attribution to a single drug, this approach exemplifies a real-time model of functional precision medicine. Rather than replacing established protocols, the assay functioned as a refinement tool, aligning drug sequencing with a previously identified tumor vulnerability. This distinction highlights its practical applicability as a decision-support strategy in prospective clinical settings. In aggressive pediatric tumors—where therapeutic windows are narrow and cumulative toxicity is a major concern—such strategies may improve treatment rationalization. The chemoresistance assessment proposed here reinforces the negative predictive value of the test—its ability to exclude ineffective agents—thereby potentially reducing unnecessary exposure, minimizing toxicity, and improving the likelihood of disease control. More broadly, this approach may contribute to reducing the use of ineffective therapies, with potential implications for healthcare costs and overall treatment burden (Tsimberidou et al. 2020, Freitas et al. 2021). It may also decrease treatment-related complications. Potential environmental implications, such as reduced pharmaceutical waste, remain speculative and warrant further investigation. Understanding resistance mechanisms also enables the development of novel therapeutic strategies and targeted agents, potentially improving efficacy while limiting toxicity (Weisenthal et al. 2015). A paradigmatic example is a reported case of diffuse midline glioma harboring the H3.3K27M mutation, a tumor associated with poor prognosis and high resistance (Tan et al. 2025). Functional drug testing combined with molecular profiling identified vulnerabilities not predicted by genomics alone, supporting treatment with disulfiram and ONC201, which resulted in significant radiological response and prolonged survival. In cases of resistance, therapeutic failure, or recurrence, ex vivo functional assays may refine treatment selection by identifying alternative agents or combinations not predicted by molecular profiling alone. This is particularly relevant in the context of increasing tumor heterogeneity and loss of response to standard therapies. More broadly, integration of functional assays with multi-omic profiling is becoming central to ongoing clinical trials in refractory pediatric tumors. The trial NCT05857969, for example, evaluates whether combining genomic profiling with ex vivo drug testing improves outcomes such as response rate and progression-free survival. This reflects the recognition that resistance is dynamic and multifactorial, requiring approaches capable of capturing tumor behavior in real time (National 2025). An emerging dimension of precision oncology involves the integration of functional chemoresistance assays with liquid biopsy approaches, particularly circulating tumor DNA (ctDNA). Liquid biopsy enables minimally invasive, longitudinal monitoring of tumor evolution, clonal dynamics, and mechanisms of resistance, which is especially valuable in pediatric neuro-oncology where repeat tissue sampling is often limited (Bardelli and Pantel 2017, Diaz and Bardelli 2014). However, while ctDNA provides real-time molecular insights, it does not preserve cellular viability and therefore does not allow direct functional assessment of drug sensitivity. Conversely, ex vivo functional assays depend on viable tumor cells to evaluate phenotypic drug response but do not capture systemic molecular evolution. These approaches should therefore be viewed as complementary rather than competing, as each interrogates distinct but convergent biological dimensions of tumor behavior. Their integration represents a promising strategy to achieve a more comprehensive and dynamic characterization of tumor biology, potentially enabling more adaptive and refined therapeutic decision-making (Wan et al. 2017). Future advances will be required to bridge these methodologies, particularly through platforms capable of linking molecular alterations identified in ctDNA with functional drug-response profiles. From a translational and clinical implementation perspective, the feasibility of incorporating functional chemoresistance assays into real-world clinical workflows is a critical consideration. In the present case, the turnaround time from tumor specimen collection to availability of functional results was approximately [7–10 days], including tissue processing, microspheroid generation, drug exposure, and viability analysis. This timeframe is compatible with clinical decision-making in recurrent and progressive pediatric CNS tumors, in which therapeutic planning often occurs within narrow time windows. These logistical characteristics support the potential integration of the Bioverso Test as a real-time decision-support tool in precision neuro-oncology, particularly in scenarios where rapid treatment adaptation is required. The discussion has been expanded to acknowledge other emerging functional approaches, including organoid-based drug screening and alternative ex vivo platforms. These strategies share the goal of improving response prediction through biologically relevant systems. Within this evolving landscape, the Bioverso Test represents a complementary methodology bridging molecular profiling and real-time drug sensitivity assessment. This study should be interpreted within the context of certain methodological considerations. As a single-case report, it provides an in-depth and hypothesis-generating perspective, although broader validation in larger cohorts will be important to establish generalizability. The use of a multimodal chemotherapy regimen reflects the complexity of real-world clinical management; however, it inherently limits the ability to attribute the observed therapeutic response to a specific agent in isolation. While the functional assay offers valuable biological insight, a direct pharmacokinetic/pharmacodynamic (PK/PD) correlation between ex vivo drug exposure and in vivo conditions was not established. The concentrations applied in the Bioverso Test (50 µM and 110 µM) follow a standardized platform design aimed at optimizing assay performance—particularly its negative predictive value and drug stability—rather than reproducing clinically achievable plasma levels. Consequently, these suprapharmacological concentrations may exceed typical pediatric Cmax values for irinotecan, and ex vivo conditions do not fully capture the complexity of in vivo pharmacokinetics and tumor–host interactions. Molecular characterization was limited to a targeted gene panel. Although clinically informative, this approach does not encompass broader genomic and epigenomic strategies, such as whole-exome sequencing, methylation profiling, or transcriptomic analyses, which could further expand the identification of biologically and clinically relevant alterations. Finally, although the initial clinical and radiological responses are encouraging, extended follow-up will be essential to more comprehensively assess the durability and long-term impact of the therapeutic response. Further validation in prospective studies and clinical trials will be essential. Nevertheless, these findings provide preliminary evidence supporting the clinical applicability of functional precision medicine in individualized therapeutic strategies. In conclusion, the Bioverso Test represents a translational functional precision medicine platform that complements molecular stratification in pediatric neuro-oncology. The use of patient-derived microspheroids preserved key aspects of tumor heterogeneity and enabled biologically meaningful drug-response assessment. In this case, the chemoresistance profile aligned with the observed clinical response and prospectively informed therapeutic prioritization within a multimodal protocol. These findings suggest that functional assays may help refine how established regimens are applied, by better matching treatment sequencing to tumor-specific vulnerabilities. More broadly, integrating functional testing with clinical, histopathological, and multi-omic data points toward a more adaptive and biologically grounded framework for therapeutic decision-making. In pediatric CNS tumors - where complexity, recurrence, and treatment-related toxicity remain major challenges - such integrated approaches may help move the field closer to truly individualized, dynamically guided therapy. Methods This study was approved by the Ethics Committee of the Pediatric Oncology Institute (GRAACC) under opinion no. 0384/2022, and by the Research Ethics Committee of the Federal University of São Paulo (UNIFESP) (CAAE no. 58018222.2.0000.5505). It was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The legal guardian of the patient (NP: 152907_pathological anatomy: clival chordoma) authorized the use of the patient’s clinical and biological data for scientific research and publication. A portion of the clival chordoma obtained during surgical resection was immediately frozen in liquid nitrogen and sent to the Biobank at the Institute of Pediatric Oncology (IOP/GRAACC/UNIFESP), where it was stored in a freezer at -80 °C until DNA and RNA extraction using the AllPrep DNA/RNA Mini Kit (QIAGEN), according to the manufacturer’s instructions. After extraction, the sample was quantified using Nanodrop 2000® and Qubit 3® fluorometers (Thermo Fisher Scientific®). Complementary DNA (cDNA) was synthesized using 20 ng of total RNA, according to the manufacturer’s protocol for SuperScript Vilo IV (Thermo Fisher Scientific®). Sequencing libraries were prepared using 20 ng of DNA and 20 ng of cDNA from each tumor sample using the OCCRA (Thermo Fisher Scientific), according to the manufacturer’s protocol. NGS using the OCCRA panel Amplicon libraries were generated using the Ion Chef system (Thermo Fisher Scientific). Sequencing was performed with 200 base-pair reads using the Ion 540™ chip on the Ion S5™ platform (Thermo Fisher Scientific). High-throughput data were generated, and read quality was assessed using the Torrent Suite software version 5.20 (Thermo Fisher Scientific). The reads obtained were aligned to the human reference genome sequence hg19/GHCh37 using the Torrent Suite software (Thermo Fisher Scientific®), and the reads had a minimum coverage of 2000×. The generated BAM files were analyzed using the Integrative Genomics Viewer software (San Diego, CA, USA). Genetic variants were classified according to class, functional effect, and clinical significance. Variant characteristics were evaluated using the COSMIC, ClinVar, VARSOME, and OncoKB databases. Tumor sample processing for evaluation of the in vitro chemoresistance platform (Bioverso test) A portion of the clival chordoma sample obtained during surgical resection was freshly fragmented into pieces smaller than 1 mm³ and enzymatically dissociated using 0.75 mg trypsin-EDTA (Gibco) and 0.3 mg collagenase + DNase (Sigma-Aldrich). The cell suspension was incubated at 37 °C with 5% CO₂ for 2 h, filtered (100 μm), and subjected to density gradient separation (Histopaque 1077) to isolate viable cells. The final cell suspension (1 × 10⁶ cells/mL) enabled the formation of three-dimensional microspheroids (< 500 μm), containing tumor cells and components of the tumor microenvironment. Chemoresistance test (Bioverso test) The Bioverso Test in vitro chemoresistance platform was initially validated using CNS tumor cell lines (U-251, M059J, A172, and U87MG) obtained from the American Type Culture Collection, representing aggressive and treatment-refractory phenotypes. Each cell line was exposed to different therapeutic agent concentrations to establish chemoresistance profiles. The drug panel included in the assay reflects a predefined platform composed of commonly used antineoplastic agents in CNS and pediatric oncology settings, selected based on prior validation and stability within the system. The agents evaluated included bleomycin, carboplatin, cyclophosphamide, cisplatin, etoposide, irinotecan, lomustine, metformin, vinblastine, vincristine, bevacizumab, topotecan, dactinomycin, and temozolomide, tested at multiple concentrations. All agents were previously incorporated into the platform and stabilized at suprapharmacological concentrations determined based on the half-maximal inhibitory concentration (IC50) values. During the validation phase, concentrations up to 10-fold higher were used to ensure the negative predictive value of the chemoresistance test, without necessarily reflecting the doses used in vivo. This methodological strategy provided an advantage over conventional assays by ensuring greater stability of the agents on the Bioverso Test platform. The microspheres were washed and plated in triplicate (~ 18 × 10³ cells/well) on the Bioverso Test platform and cultured for 72 h in Dulbecco’s Modified Eagle’s Medium-Low Glucose (DMEM-LG; GIBCO/Invitrogen Corporation), supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic solution (100×), and 1% L-glutamine (200 mM, 100×) in a humidified incubator at 37 °C with 5% CO₂ (Thermo Fisher Scientific, Waltham, MA, USA). Cell viability was determined using the MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) with a 5 mg/mL solution incubated for 2 h. After removal of the reagent, 100 µL of dimethyl sulfoxide was added, followed by incubation for 30 min at 37 °C. Optical density was measured at 570 nm using a microplate reader (ELISA), reflecting cellular mitochondrial activity. Cell viability was expressed as a percentage relative to the untreated control. Resistance was classified as low (< 40%), intermediate (40–60%), or high (> 60%). Assessment of cell death by flow cytometry To confirm the cytotoxic effect, clival chordoma cells were incubated with DMEM-LG (control) and irinotecan at concentrations CP-11 D1 [50 µM] and CP-11 D2 [110 µM] for 72 h. After washing with cold phosphate-buffered saline solution, 10⁵ cells were resuspended in 100 µL of 1X binding buffer (Molecular Probes, Invitrogen) and labeled with 5 µL FITC-Annexin V and 5 µL propidium iodide (PI) (BD Biosciences). The samples were incubated for 15 min in the dark at room temperature, brought to 500 µL with 1X binding buffer, and analyzed on an LSR Fortessa flow cytometer (BD Biosciences) within 1 h. Data analysis was performed using the FlowJo software. This assay enabled quantification of apoptotic and necrotic cells, confirming the efficacy of the selected agent. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Acknowledgments: The National Council for Scientific and Technological Development, Ministry of Science, Technology and Innovation (CNPq, MCTI, INCT BioOncoPed, Brazil). This study was funded by the National Council for Scientific and Technological Development, Ministry of Science, Technology and Innovation (CNPq, MCTI, INCT BioOncoPed, Brazil) [grant number: 406484/2022–8] and by the National Council for Scientific and Technological Development- CNPq (PQ2) [Process. N. 309215/202–0]. Author contributions All authors contributed to data analysis and interpretation. All authors critically reviewed the manuscript during development and approved the final version. All authors agreed to be accountable for the accuracy and integrity of the data presented here. Funding This study was funded by the National Council for Scientific and Technological Development, Ministry of Science, Technology and Innovation (CNPq, MCTI, INCT BioOncoPed, Brazil) [grant number: 406484/2022–8] and by the National Council for Scientific and Technological Development- CNPq (PQ2) [Process. N. 309215/202–0]. Data availability This research did not generate data. Declarations Ethical approval This study was approved by the Federal University of São Paulo, Brazil Ethics Committee (CAAE: 58018222.2.0000.5505. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent to Publish All authors agree to be accountable for the accuracy and integrity of the data presented here. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Sérgio Cavalheiro, Email: sergiocavalheironeuro@gmail.com. Lorena Favaro Pavon, Email: l.pavon@unifesp.br. Marcos Devanir Silva da Costa, Email: marcoscostaneuro@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement This research did not generate data.